{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T01:38:01Z","timestamp":1649036281343},"reference-count":20,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.3960\/jslrt.21004","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T22:13:41Z","timestamp":1625004821000},"page":"162-167","source":"Crossref","is-referenced-by-count":0,"title":["A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma"],"prefix":"10.3960","volume":"61","author":[{"given":"Kazunori","family":"Ohnishi","sequence":"first","affiliation":[{"name":"Department of Hematology, Hamamatsu University School of Medicine, Hamamatsu, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohmachi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Tokai University, Isehara, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Tokai University, Isehara, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Hematology, Anjo Kosei Hospital, Anjo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsune","family":"Tanimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaneyuki","family":"Ohbayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toyota Memorial Hospital, Toyota, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Medical University, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayo","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shiga General Hospital, Moriyama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamamatsu University School of Medicine, Hamamatsu, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Miyamura","sequence":"additional","affiliation":[{"name":"Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitoyo","family":"Kagami","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toyota Kosei Hospital, Toyota, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomitsu","family":"Hotta","sequence":"additional","affiliation":[{"name":"National Hospital Organization Nagoya Medical Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Chihara D, Ito H, Matsuda T <i>et al.<\/i> Differences in incidence and trends of haematological malignancies in J apan and the United States. Br J Haematol. 2014; 164: 536-545.","DOI":"10.1111\/bjh.12659"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Leonard JP, Nastoupil LJ, Flowers CR. Where to start? Upfront therapy for follicular lymphoma in 2018. Hematology (Am Soc Hematol Educ Program). 2018; 2018: 185-188.","DOI":"10.1182\/asheducation-2018.1.185"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Luminari S, Ferrari A, Manni M <i>et al.<\/i> Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018; 36: 689-696.","DOI":"10.1200\/JCO.2017.74.1652"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Rummel MJ, Niederle N, Maschmeyer G <i>et al.<\/i> Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381: 1203-1210.","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Flinn IW, van der Jagt R, Kahl B <i>et al.<\/i> First-Line Treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell Lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019; 37: 984-991.","DOI":"10.1200\/JCO.18.00605"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Wu SJ, Chen YC, Lo WC <i>et al.<\/i> Distinctive incidence patterns of follicular lymphoma in Taiwan: implications of ethnic differences. Cancer Med. 2019; 8: 1899-1907.","DOI":"10.1002\/cam4.2028"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Mori M, Kitamura K, Masuda M <i>et al.<\/i> Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin\u2019s lymphoma. Int J Hematol. 2005; 81: 246-254.","DOI":"10.1532\/IJH97.03147"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Harris NL, Jaffe ES, Diebold J <i>et al.<\/i> World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting\u2014Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 3835-3849.","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Czuczman MS, Grillo-L\u00f3pez AJ, White CA <i>et al.<\/i> Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999; 17: 268-276.","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Cheson BD, Horning SJ, Coiffier B <i>et al.<\/i> Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol. 1999; 17: 1244-1253.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Solal-C\u00e9ligny P, Roy P, Colombat P <i>et al.<\/i> Follicular lymphoma international prognostic index. Blood. 2004; 104: 1258-1265.","DOI":"10.1182\/blood-2003-12-4434"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Umezawa H, Takahashi Y, Kinoshita M <i>et al.<\/i> Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot (Tokyo). 1979; 32: 1082-1084.","DOI":"10.7164\/antibiotics.32.1082"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Dantchev D, Paintrand M, Hayat M, Bourut C, Math\u00e9 G. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot (Tokyo). 1979; 32: 1085-1086.","DOI":"10.7164\/antibiotics.32.1085"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Bastion Y, Blay JY, Divine M <i>et al.<\/i> Elderly patients with aggressive non-Hodgkin\u2019s lymphoma: disease presentation, response to treatment, and survival--a Groupe d\u2019Etude des Lymphomes de l\u2019Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997; 15: 2945-2953.","DOI":"10.1200\/JCO.1997.15.8.2945"},{"key":"15","unstructured":"15 Ogura M, Chou T, Hotta T <i>et al.<\/i> Phase I\/II Study of THP-COP Therapy for old-age patients with advanced-stage aggressive non-Hodgkin\u2019s lymphoma (NHL): of Lymphoma phase I Study Group (LPOSG) Study on 30 patients older than 70 years [abstract]. Blood. 2001; [abstract 4708]."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Tsurumi H, Yamada T, Sawada M <i>et al.<\/i> Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin\u2019s lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol. 2004; 130: 107-113.","DOI":"10.1007\/s00432-003-0508-9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Hiddemann W, Kneba M, Dreyling M <i>et al.<\/i> Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106: 3725-3732.","DOI":"10.1182\/blood-2005-01-0016"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Watanabe T, Tobinai K, Shibata T <i>et al.<\/i> Phase II\/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin\u2019s lymphoma: JCOG 0203 trial. J Clin Oncol. 2011; 29: 3990-3998.","DOI":"10.1200\/JCO.2011.34.8508"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Coiffier B, Lepage E, Bri\u00e8re J <i>et al.<\/i> CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235-242.","DOI":"10.1056\/NEJMoa011795"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Seymour JF, Marcus R, Davies A <i>et al.<\/i> Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019; 104: 1202-1208.","DOI":"10.3324\/haematol.2018.209015"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/3\/61_21004\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T04:21:46Z","timestamp":1631334106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/3\/61_21004\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.21004","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"21004"}}